Saturday, January 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

BioFire Receives FDA Clearance for the FilmArray 2.0

by Global Biodefense Staff
February 26, 2015
BioWatch Trigger Detector

BioFire Diagnostics, LLC today announced that it has received FDA clearance and CE-IVD marking of the FilmArray 2.0 system. The system is expected to be commercially available by the end of March 2015.

Since its acquisition by bioMérieux, BioFire Diagnostics has reported more than 60% organic growth in sales at the end of 2014.

FilmArray 2.0 features higher throughput, allowing customers random access processing up to 175 samples in a day within a small footprint. The system offers the same strengths of rapidity, ease-of-use, integration and accuracy that characterize the current FilmArray. Each system accommodates 1 to 8 FilmArray 2.0 units operated by a single computer. The system is also capable of connecting to Laboratory Information Systems.

“As we develop additional applications for the FilmArray system, it is essential that customers are able to accommodate high throughput with as small of a footprint as possible,” said Randy Rasmussen, bioMérieux Corporate Vice President of Molecular Biology and CEO of BioFire Diagnostics. “We look forward to introducing the FilmArray 2.0 system to clinical laboratories throughout the world and are excited for the expected benefits FilmArray’s syndromic approach will have on the fight against infectious diseases, antibiotic stewardship and more broadly on patient care and healthcare cost reduction.”

Currently, the FilmArray menu includes three FDA-cleared and CE-marked panels: the Respiratory Panel, the Blood Culture Identification Panel and the Gastrointestinal Panel.

Additionally, BioFire has initiated studies for its Meningitis-Encephalitis Panel, with FDA submission expected this year.

Tags: BioterrorismBioWatch

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC